By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NeuroVive Pharmaceutical AB 

Biomedical Center

Sölvegatan 19    SE-221 84 Lund  Sweden
Phone: 46-0-46-288-0110 Fax: 46-0-46-888-8348


NeuroVive Pharmaceutical is a pioneer in mitochondrial research and development. The focus is on developing drug candidates that maintain mitochondrial integrity and improves their function for indications with unmet medical needs. Research and development is conducted both in-house and in collaboration with renowned international partners.




Founder: Eskil Elmér

CEO: Erik Kinnman

CSO and Founder: Eskil Elmér

Key Statistics

Ownership: Public

Web Site: NeuroVive
Symbol: NVP


Company News
NeuroVive (NVP) Completes Closure Of Lyon Subsidiary 10/25/2016 11:25:06 AM
NeuroVive (NVP) Ends Deal With Arbutus Biopharma (ABUS), Takes Back Hep B Drug 10/21/2016 5:56:26 AM
NeuroVive (NVP) Stock Craters After Discontinuing Acute Kidney Injury Program 10/13/2016 5:40:51 AM
NeuroVive (NVP) To Present At The Rodman & Renshaw 18th Annual Global Investment Conference 9/7/2016 1:39:02 PM
NeuroVive (NVP) Announces That The Clinical Study Ciprics Will Be Presented At The Swedish Thorax Meeting In October 2016 8/30/2016 1:09:13 PM
NeuroVive (NVP)'s COO Resigns 8/24/2016 5:47:33 AM
NeuroVive (NVP) - Interim Report January-June 2016 8/18/2016 1:47:03 PM
NeuroVive (NVP) Completes 10 Percent Acquisition Of Isomerase Therapeutics 8/15/2016 9:42:26 AM
NeuroVive (NVP)’s Novel Strategy For Treatment Of Mitochondrial Disease Published In Nature Communications 8/9/2016 10:05:13 AM
NeuroVive (NVP) Announces Arbutus Biopharma (ABUS)’s Notice Of Termination 7/6/2016 10:05:04 AM